- Trials with a EudraCT protocol (125)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
125 result(s) found for: Sigmoidoscopy.
Displaying page 1 of 7.
EudraCT Number: 2013-000452-18 | Sponsor Protocol Number: CB-17-03/01 | Start Date*: 2013-03-21 | |||||||||||
Sponsor Name:Cosmo Technologies Ltd. | |||||||||||||
Full Title: Staining efficacy and safety of Methylene Blue enemas in patients undergoing flexible rectosigmoidoscopy | |||||||||||||
Medical condition: Out-patients of both sexes with indication for diagnostic flexible rectosigmoidoscopy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011248-21 | Sponsor Protocol Number: | Start Date*: 2009-06-29 |
Sponsor Name: | ||
Full Title: het optimaliseren van de voorbereiding voor sigmoidoscopie in de regio; Moviprep versus Bisacodyl/klysma, een enkelblind gerandomiseerd onderzoek | ||
Medical condition: Bowel preparation for sigmoidoscopy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004077-29 | Sponsor Protocol Number: 2004112 | Start Date*: 2005-02-04 |
Sponsor Name:Procter & Gamble Pharmaceuticals | ||
Full Title: A Double-blind, Randomized, Multicenter, Active-control, 56-day Study with a 28-day Follow-up to Assess the Efficacy and Safety of RDP58 200 mg/day plus Mesalazine 2.4 g/day and RDP58 600 mg/day pl... | ||
Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) LT (Completed) SK (Completed) CZ (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003319-64 | Sponsor Protocol Number: S3B40042 | Start Date*: 2007-07-05 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects | ||
Medical condition: Irritable Bowel Syndrome (IBS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000733-12 | Sponsor Protocol Number: SPD476-301 | Start Date*: 2004-07-14 |
Sponsor Name:Shire Pharmaceutical Development Inc | ||
Full Title: A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 g... | ||
Medical condition: Subjects who have newly diagnosed or have a diagnosis of relapsing (relapses | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002976-14 | Sponsor Protocol Number: CRI103143 | Start Date*: 2006-09-27 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of ... | ||
Medical condition: Irritable Bowel Syndrome (IBS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-006118-17 | Sponsor Protocol Number: B3I105940 | Start Date*: 2006-08-17 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome | ||
Medical condition: Irritable Bowel Syndrome (IBS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003724-19 | Sponsor Protocol Number: 197-02-218 | Start Date*: 2005-10-24 | |||||||||||
Sponsor Name:Otsuka Maryland Research Institute, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis | |||||||||||||
Medical condition: Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002136-24 | Sponsor Protocol Number: 0157 | Start Date*: 2019-09-10 | |||||||||||
Sponsor Name:Theravance Biopharma Ireland Limited | |||||||||||||
Full Title: A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1... | |||||||||||||
Medical condition: Moderately-to-Severely Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Completed) SK (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended) PL (Completed) GR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004384-75 | Sponsor Protocol Number: 37970 | Start Date*: 2012-09-10 | ||||||||||||||||
Sponsor Name: | ||||||||||||||||||
Full Title: Randomized controlled trial: Picoprep versus Moviprep for efficacy, safety and patient tolerability in colonoscopy bowel preparation. | ||||||||||||||||||
Medical condition: Patients who need a colonoscopy for screening, surveillance or diagnosis of a disease have to be prepared by bowel cleansing | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000611-25 | Sponsor Protocol Number: 197-02-220 | Start Date*: 2004-10-15 |
Sponsor Name:Otsuka Maryland Research Institute, Inc. | ||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in... | ||
Medical condition: Maintenance of remission of ulcerative colitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000848-24 | Sponsor Protocol Number: SB-223412/068 | Start Date*: 2004-10-26 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome | |||||||||||||
Medical condition: Irritable Bowel Syndrome (IBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Prematurely Ended) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001310-32 | Sponsor Protocol Number: 2006444 | Start Date*: 2006-06-16 | |||||||||||
Sponsor Name:Procter & Gamble Technical Centres Limited | |||||||||||||
Full Title: A double-blind, randomized, 6-week, parallel-group clinical trial to assess the safety and efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet)... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) CZ (Completed) HU (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002784-91 | Sponsor Protocol Number: HAW0501 | Start Date*: 2006-02-06 |
Sponsor Name:Cardiff and Vale NHS Trust | ||
Full Title: A Randomized, Multicentre, Parallel Group Single-Blind Study to Assess the Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily versus Divided Doses Three Times Dai... | ||
Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018340-14 | Sponsor Protocol Number: 10085 | Start Date*: 2010-11-25 | |||||||||||
Sponsor Name:University of Nottingham | |||||||||||||
Full Title: Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). | |||||||||||||
Medical condition: Diarrhoea-predominant irritable bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005215-16 | Sponsor Protocol Number: CHUB-MentalRecup001 | Start Date*: 2015-02-13 | |||||||||||
Sponsor Name:CHU Brugmann | |||||||||||||
Full Title: A psychomotor recuperation study after deep sedation for colonoscopy between target controlled and manual titration of propofol. | |||||||||||||
Medical condition: Ambulatory colonoscopy with sedation by target controlled infusion or manual titration of propofol. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000734-36 | Sponsor Protocol Number: SPD476-303 | Start Date*: 2005-07-13 |
Sponsor Name:Shire Pharmaceutical Development Inc. | ||
Full Title: A phase III, randomized, multi-center, open-label, 12 to 14 months extension study to evaluate the safety and tolerability of SPD476 (mesalazine) give once daily vs. twice daily for the maintenance... | ||
Medical condition: Subject not in remission of Ulcerative Colitis (UC-DAI score of >1) at the End of Study/Early Withdrawal Visit of Study 301 or 302. Subject in remission of UC (UC-DAI<1 with a score of 0 for rectal... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005166-12 | Sponsor Protocol Number: HMPL-004-US-02 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:Hutchison MediPharma Enterprises Limited | |||||||||||||
Full Title: A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine | |||||||||||||
Medical condition: active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003193-48 | Sponsor Protocol Number: Darvadstrocel-3004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn’s Disease over a Period o... | |||||||||||||
Medical condition: Complex Perianal Fistulas in Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003703-22 | Sponsor Protocol Number: P2-IMU-838-UC | Start Date*: 2018-05-03 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe u... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) PL (Completed) PT (Completed) HR (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
